Comparative Pharmacology
Head-to-head clinical analysis: CAPOTEN versus UNIVASC.
Peer-Reviewed Evidence
Head-to-head clinical analysis: CAPOTEN versus UNIVASC.
CAPOTEN vs UNIVASC
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Competitive inhibitor of angiotensin-converting enzyme (ACE), preventing conversion of angiotensin I to angiotensin II, leading to decreased vasoconstriction, reduced aldosterone secretion, and increased plasma renin activity.
Angiotensin-converting enzyme (ACE) inhibitor; inhibits conversion of angiotensin I to angiotensin II, reducing vasoconstriction and aldosterone secretion, leading to decreased blood pressure.
50 mg orally three times daily initially; maintenance 50-100 mg three times daily; maximum 450 mg/day.
Initial: 7.5 mg orally once daily; titrate to 15-30 mg once daily. Maximum: 60 mg/day.
None Documented
None Documented
Terminal elimination half-life is approximately 1.9 hours in healthy subjects, but prolonged in heart failure (up to 3-4 hours) and renal impairment (up to 5-10 hours).
The terminal elimination half-life of moexiprilat, the active metabolite, is approximately 9.8 hours in patients with normal renal function. This supports once-daily dosing, though the antihypertensive effect may persist beyond 24 hours with continued therapy.
Primarily renal (approximately 60-75% as unchanged drug and metabolites) and biliary/fecal (approximately 20%).
Univasc (moexipril) is primarily eliminated via renal excretion (approximately 50% of absorbed dose as unchanged drug and metabolites) and fecal excretion (about 50%).
Category C
Category C
ACE Inhibitor
ACE Inhibitor